Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW -- Ignore unavailable to you. Want to Upgrade?

To: Marty who wrote (473)	10/12/1998 8:13:00 PM
From: Mad2	Read Replies (1) \| Respond to of 857

Marty, There are two types of shorts. The first is a patient short who looks for hyped stocks that have poor prospects to support their stock price longer term, the second is of course the very impatient type looking for a quick buck. Many of the latter are gone. As you say this is a arm wrestling contest. What Carter has going for him is a product that is very difficult to evaluate in that it is diagonised by default and apparently very troublesome to those that have it. This diagonsis aspect makes it very prone to abuse and from what I have read that's my assessment of of HEB's approach. Unlike other deseases where the the diagonosis and benifit of treatment is more clear cut. If you believe Asensio's report (I do) it doesn't say much for how the rest of CFS community assess's HEB's Ampligen and work. Also I look at what Asensio has written, it certianly is subject to review. Fundamentally what Carter say's about Ampligen is much less definitive, open to interpretation. Anyway again time will tell with this one. If I could have gotten some shares shorted this afternoon I would have sold as much as I could have gotten my hands on.